The Scott M. Hammer Annual Update on HIV Management in New York, New York (Offered In-Person and Virtually)

Last Modified: Oct 14, 2026 @ 8:56 AM

Program Description

Stay current with the latest advances shaping HIV care at the annual Scott M. Hammer Annual Update on HIV Management in New York. This 1-day course brings together leading experts for timely clinical updates, practical guidance, and engaging case-based discussions designed for clinicians caring for people with HIV.

The program will highlight key updates from CROI 2027 and beyond, including new and investigational drugs and formulations. Faculty will discuss the latest developments in HIV and sexually transmitted infection (STI) prevention and work through challenging antiretroviral therapy (ART) and drug resistance cases. The course will also provide practical updates on primary care for people with HIV and explore special considerations for adolescents and young adults with perinatally acquired HIV.

Additional sessions will examine GLP-1 receptor agonists at the intersection of HIV and addiction, dermatologic manifestations of HIV and STIs, and the growing role of artificial intelligence and other technological innovations in HIV care and prevention.

Join us in person in New York City or virtually for a focused day of expert insights, interactive discussion, and practical takeaways for your clinical practice.

IAS–USA Lifetime of Leadership Award

At this course, the IAS–USA is proud to present its Lifetime of Leadership Award—established to honor individuals whose contributions have left a profound and lasting impact on HIV medicine, scientific education, and the mission of the IAS–USA—to Paul A. Volberding, MD, founding Chair of the IAS–USA Board of Directors, in recognition of his longstanding leadership and contributions to the field of HIV medicine.

Additional information about the award presentation and celebration to come.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of clinicians involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV and related comorbidities. Information will be presented through a mix of didactic lectures, clinically relevant cases, and panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement current recommendations for initiating and changing antiretroviral therapy in challenging clinical circumstances, including different patterns of drug resistance and other considerations that affect treatment selection
• Apply current HIV and STI prevention recommendations in clinical practice
• Discuss important considerations in the care of adolescents and young adults with perinatally acquired HIV as they transition to adult care
• Review emerging data on GLP-1 receptor agonists and their potential applications at the intersection of HIV and addiction
• Recognize common and challenging dermatologic manifestations of HIV and STIs
• Incorporate current primary care recommendations and screening guidance into the care of people with HIV

Preliminary Topics

• Difficult cases in antiretroviral therapy
• Key updates from CROI 2027 and beyond: investigational drugs and emerging therapies
• HIV and STI prevention updates
• Perinatal HIV: special considerations for adolescents and young adults
• GLP-1 receptor agonists: the intersection of HIV and addiction
• Dermatologic manifestations of HIV and STIs
• Primary care for people with HIV: key updates and practical considerations

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.